Clearside Biomedical
CLSD
CLSD was delisted on the 28th of November, 2025.
79 hedge funds and large institutions have $211M invested in Clearside Biomedical in 2018 Q1 according to their latest regulatory filings, with 34 funds opening new positions, 28 increasing their positions, 9 reducing their positions, and 9 closing their positions.
278% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 9
246% more call options, than puts
Call options by funds: $1.04M | Put options by funds: $301K
211% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 9
144% more capital invested
Capital invested by funds: $86.3M → $211M (+$124M)
46% more funds holding
Funds holding: 54 → 79 (+25)
0.86% more ownership
Funds ownership: 3.24% → 4.1% (+0.86%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$13.5M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$12.4M |
| 3 |
Millennium Management
New York
|
+$11.1M |
| 4 |
MWNA
Marshall Wace North America
New York
|
+$5.21M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$4.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
-$6.61M |
| 2 |
First Manhattan
New York
|
-$1.42M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$1.42M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$487K |
| 5 |
WS
Wedbush Securities
Los Angeles,
California
|
-$342K |
CLSD Hedge Fund Activity: Q1 2018 in Review
79 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Clearside Biomedical (CLSD) for Q1 2018, worth a combined $211M — up 144% from $86.3M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new CLSD positions and 9 closed out — a net gain of 25 holders — while 28 added to existing stakes and 9 trimmed.
The largest buyer was Wellington Management Group, adding an estimated $13.5M. The largest seller was Hillhouse Investment Management, exiting entirely with an estimated $6.61M sold.
- 79 institutional investors held Clearside Biomedical (CLSD) as of Q1 2018, up from 54 in Q4 2017.
- Funds reported $211M of Clearside Biomedical stock for Q1 2018, up 144% quarter-over-quarter.
- 34 funds opened new Clearside Biomedical positions in Q1 2018 and 9 closed out, a net change of +25 holders.
- The largest Clearside Biomedical buyer in Q1 2018 was Wellington Management Group, an estimated $13.5M added.
- The largest Clearside Biomedical seller in Q1 2018 was Hillhouse Investment Management, an estimated $6.61M sold.
Based on aggregated 13F filings for Q1 2018.